Literature DB >> 22926313

Stroke: secondary stroke prevention--personalized antiplatelet therapy.

David Tanne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22926313     DOI： 10.1038/nrneurol.2012.180

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study.

Authors:  Jean-Luc Reny; Philippe Berdagué; Antoine Poncet; Isabelle Barazer; Séverine Nolli; Pascale Fabbro-Peray; Jean-François Schved; Henri Bounameaux; François Mach; Philippe de Moerloose; Pierre Fontana
Journal:  Circulation       Date:  2012-05-21       Impact factor: 29.690

Review 2.  Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis.

Authors:  C Combescure; P Fontana; N Mallouk; P Berdague; C Labruyere; I Barazer; J C Gris; S Laporte; P Fabbro-Peray; J L Reny
Journal:  J Thromb Haemost       Date:  2010-02-12       Impact factor: 5.824

3.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

4.  Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.

Authors:  Jeremiah P Depta; Jeffrey Fowler; Eric Novak; Irene Katzan; Suzanne Bakdash; Kandice Kottke-Marchant; Deepak L Bhatt
Journal:  Stroke       Date:  2012-06-19       Impact factor: 7.914

5.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

6.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

Review 7.  Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

Authors:  Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; J Wouter Jukema; Menno V Huisman
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

Review 8.  Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis.

Authors:  Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; Menno V Huisman
Journal:  Arch Intern Med       Date:  2007 Aug 13-27

9.  Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.

Authors:  Y Schwammenthal; R Tsabari; B Shenkman; R Schwartz; S Matetzky; A Lubetsky; D Orion; S Israeli-Korn; J Chapman; N Savion; D Varon; D Tanne
Journal:  Cerebrovasc Dis       Date:  2008-02-28       Impact factor: 2.762

10.  High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial).

Authors:  Alf-Åge R Pettersen; Ingebjørg Seljeflot; Michael Abdelnoor; Harald Arnesen
Journal:  J Am Heart Assoc       Date:  2012-06-22       Impact factor: 5.501
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.